Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 23.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 17.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ployee severance and termination payments. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 11.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Unternehmen & Branche
| Name | NEKTAR THERAPEUTICS |
|---|---|
| Ticker | NKTR |
| CIK | 0000906709 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 640268108 |
|---|---|
| ISIN | US6402681083 |
| Typ | Common Stock |
| Marktkapitalisierung | 1,68 Mrd. USD |
| Beta | 1,25 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 55,232,000 | -164,076,000 | -9.73 | 280,406,000 | 89,832,000 |
| 2025-09-30 | 10-Q | 11,790,000 | -35,522,000 | -1.87 | 301,347,000 | 85,086,000 |
| 2025-06-30 | 10-Q | 11,175,000 | -41,593,000 | -2.95 | 207,534,000 | -24,211,000 |
| 2025-03-31 | 10-Q | 10,460,000 | -50,882,000 | -0.24 | 256,241,000 | 13,738,000 |
| 2024-12-31 | 10-K | 98,427,000 | -118,961,000 | -8.68 | 303,850,000 | 60,737,000 |
| 2024-09-30 | 10-Q | 24,124,000 | -37,057,000 | -2.66 | 307,966,000 | 48,884,000 |
| 2024-06-30 | 10-Q | 23,489,000 | -52,363,000 | -3.76 | 343,334,000 | 79,688,000 |
| 2024-03-31 | 10-Q | 21,639,000 | -36,802,000 | -0.19 | 396,012,000 | 126,705,000 |
| 2023-12-31 | 10-K | 90,122,000 | -276,056,000 | -1.45 | 398,033,000 | 130,987,000 |
| 2023-09-30 | 10-Q | 24,144,000 | -45,837,000 | -0.24 | 442,244,000 | 159,368,000 |
| 2023-06-30 | 10-Q | 20,499,000 | -51,122,000 | -0.27 | 494,279,000 | 196,958,000 |
| 2023-03-31 | 10-Q | 21,594,000 | -137,018,000 | -0.73 | 561,743,000 | 240,865,000 |
| 2022-12-31 | 10-K | 92,055,000 | -368,198,000 | -1.97 | 710,600,000 | 366,638,000 |
| 2022-09-30 | 10-Q | 23,625,000 | -59,049,000 | -0.31 | 781,006,000 | 412,223,000 |
| 2022-06-30 | 10-Q | 21,585,000 | -159,068,000 | -0.85 | 861,987,000 | 458,732,000 |
| 2022-03-31 | 10-Q | 24,822,000 | -90,393,000 | -0.49 | 1,024,116,000 | 607,889,000 |
| 2021-12-31 | 10-K | 25,009,000 | -145,645,000 | -790.00 | 1,117,189,000 | 679,508,000 |
| 2021-09-30 | 10-Q | 24,921,000 | -129,706,000 | -0.70 | 1,277,243,000 | 801,540,000 |
| 2021-09-30 | 10-K | 24,921,000 | -129,706,000 | -700.00 | ||
| 2021-06-30 | 10-K | 28,330,000 | -125,519,000 | -690.00 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,158,310 | 0 | 1,158,310 | 48,973,346 | Neu | +100,0% | |
| VANGUARD GROUP INC | 1,027,089 | 0 | 1,027,089 | 43,425,322 | Neu | +100,0% | |
| Bronte Capital Management Pty Ltd. | 400,756 | 0 | 400,756 | 28,834,394 | Neu | +100,0% | |
| BlackRock, Inc. | 645,607 | 0 | 645,607 | 27,296,262 | Neu | +100,0% | |
| MORGAN STANLEY | 566,421 | 0 | 566,421 | 23,948,280 | Neu | +100,0% | |
| UBS Group AG | 320,172 | 287,561 | 32,611 | 23,036,375 | Aufgestockt | +11,3% | |
| CITADEL ADVISORS LLC | 489,377 | 0 | 489,377 | 20,690,859 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 473,014 | 0 | 473,014 | 19,999,032 | Neu | +100,0% | |
| Invesco Ltd. | 468,159 | 0 | 468,159 | 19,793,774 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 454,075 | 0 | 454,075 | 19,198,291 | Neu | +100,0% | |
| EMERALD ADVISERS, LLC | 384,342 | 0 | 384,342 | 16,249,980 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 323,915 | 0 | 323,915 | 13,695,126 | Neu | +100,0% | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 295,716 | 0 | 295,716 | 12,502,872 | Neu | +100,0% | |
| PRIMECAP MANAGEMENT CO/CA/ | 280,150 | 0 | 280,150 | 11,844,742 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 254,361 | 0 | 254,361 | 10,757,656 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 224,837 | 0 | 224,837 | 9,506,109 | Neu | +100,0% | |
| BNP PARIBAS FINANCIAL MARKETS | 210,298 | 0 | 210,298 | 8,891,399 | Neu | +100,0% | |
| GILDER GAGNON HOWE & CO LLC | 208,302 | 0 | 208,302 | 8,807,009 | Neu | +100,0% | |
| STATE STREET CORP | 195,656 | 0 | 195,656 | 8,272,336 | Neu | +100,0% | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 188,112 | 0 | 188,112 | 7,953,375 | Neu | +100,0% | |
| Russell Investments Group, Ltd. | 106,248 | 85,666 | 20,582 | 7,644,546 | Aufgestockt | +24,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 172,881 | 0 | 172,881 | 7,309,409 | Neu | +100,0% | |
| Caption Management, LLC | 160,000 | 0 | 160,000 | 6,764,800 | Neu | +100,0% | |
| MOODY ALDRICH PARTNERS LLC | 89,527 | 56,023 | 33,504 | 6,441,468 | Aufgestockt | +59,8% | |
| JPMORGAN CHASE & CO | 150,804 | 0 | 150,804 | 6,375,993 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 147,793 | 0 | 147,793 | 6,248,688 | Neu | +100,0% | |
| GROUP ONE TRADING LLC | 144,648 | 0 | 144,648 | 6,115,717 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 120,380 | 0 | 120,380 | 5,089,666 | Neu | +100,0% | |
| Nantahala Capital Management, LLC | 112,946 | 0 | 112,946 | 4,775,357 | Neu | +100,0% | |
| Jefferies Financial Group Inc. | 111,900 | 0 | 111,900 | 4,731,132 | Neu | +100,0% | |
| Connor, Clark & Lunn Investment Management Ltd. | 101,166 | 0 | 101,166 | 4,277,298 | Neu | +100,0% | |
| FMR LLC | 101,129 | 0 | 101,129 | 4,275,734 | Neu | +100,0% | |
| SIMPLEX TRADING, LLC | 94,636 | 0 | 94,636 | 4,001,210 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 90,743 | 0 | 90,743 | 3,836,614 | Neu | +100,0% | |
| Quinn Opportunity Partners LLC | 85,868 | 0 | 85,868 | 3,630,499 | Neu | +100,0% | |
| Swiss National Bank | 47,900 | 31,900 | 16,000 | 3,446,405 | Aufgestockt | +50,2% | |
| DAFNA Capital Management LLC | 74,998 | 0 | 74,998 | 3,170,915 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 72,031 | 0 | 72,031 | 3,045,471 | Neu | +100,0% | |
| Nearwater Capital Markets, Ltd | 61,500 | 0 | 61,500 | 2,600,220 | Neu | +100,0% | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 60,431 | 0 | 60,431 | 2,555,023 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 59,691 | 0 | 59,691 | 2,523,735 | Neu | +100,0% | |
| F/m Investments LLC | 58,123 | 0 | 58,123 | 2,457,440 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 56,076 | 0 | 56,076 | 2,370,893 | Neu | +100,0% | |
| Aquatic Capital Management LLC | 55,240 | 0 | 55,240 | 2,335,547 | Neu | +100,0% | |
| FRED ALGER MANAGEMENT, LLC | 54,020 | 0 | 54,020 | 2,283,966 | Neu | +100,0% | |
| NORGES BANK | 50,000 | 0 | 50,000 | 2,114,000 | Neu | +100,0% | |
| Y-Intercept (Hong Kong) Ltd | 26,545 | 10,862 | 15,683 | 1,909,913 | Aufgestockt | +144,4% | |
| DARK FOREST CAPITAL MANAGEMENT LP | 42,277 | 0 | 42,277 | 1,787,472 | Neu | +100,0% | |
| Headlands Technologies LLC | 41,201 | 0 | 41,201 | 1,741,978 | Neu | +100,0% | |
| AWM Investment Company, Inc. | 40,000 | 0 | 40,000 | 1,691,200 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -180 | 73.00 | -13,140.00 | -27,9% | |
| 2026-02-18 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -423 | 73.00 | -30,879.00 | -65,5% | |
| 2026-01-20 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -3,867 | 35.67 | -137,935.89 | -292,6% | |
| 2025-11-25 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -2,207 | 54.28 | -119,795.96 | -254,1% | |
| 2025-11-25 | Wilson Mark Andrew | Officer, Chief Legal Officer | Open Market Sale | -630 | 54.28 | -34,196.40 | -72,5% | |
| 2025-11-25 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -1,157 | 54.28 | -62,801.96 | -133,2% | |
| 2025-09-09 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1,210 | 48.18 | -58,297.80 | -123,7% | |
| 2025-09-09 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -2,156 | 47.49 | -102,388.44 | -217,2% | |
| 2025-09-09 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -2,100 | 45.16 | -94,836.00 | -201,2% | |
| 2025-09-09 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1,200 | 46.41 | -55,692.00 | -118,2% | |
| 2025-09-05 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -3,304 | 37.87 | -125,122.48 | -265,4% | |
| 2025-09-05 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1,136 | 39.89 | -45,315.04 | -96,1% | |
| 2025-09-05 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -2,226 | 38.82 | -86,413.32 | -183,3% | |
| 2025-09-04 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -613 | 34.40 | -21,087.20 | -44,7% | |
| 2025-09-04 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1,923 | 32.37 | -62,247.51 | -132,1% | |
| 2025-09-04 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -189 | 34.41 | -6,503.49 | -13,8% | |
| 2025-09-04 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -307 | 35.69 | -10,956.83 | -23,2% | |
| 2025-09-04 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -432 | 33.60 | -14,515.20 | -30,8% | |
| 2025-09-04 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -793 | 32.43 | -25,716.99 | -54,6% | |
| 2025-09-04 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1,496 | 33.54 | -50,175.84 | -106,4% | |
| 2025-09-04 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1,134 | 35.80 | -40,597.20 | -86,1% | |
| 2025-09-02 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -485 | 30.10 | -14,598.50 | -31,0% | |
| 2025-09-02 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1,500 | 30.16 | -45,240.00 | -96,0% | |
| 2025-08-19 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -725 | 26.59 | -19,277.75 | -40,9% | |
| 2025-08-19 | Wilson Mark Andrew | Officer, Chief Legal Officer | Open Market Sale | -676 | 26.59 | -17,974.84 | -38,1% | |
| 2025-08-19 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -1,573 | 26.59 | -41,826.07 | -88,7% | |
| 2025-05-19 | Wilson Mark Andrew | Officer, Chief Legal Officer | Open Market Sale | -9,996 | 0.67 | -6,697.32 | -14,2% | |
| 2025-05-19 | ROBIN HOWARD W | Director, Officer, President & CEO | Open Market Sale | -23,208 | 0.67 | -15,549.36 | -33,0% | |
| 2025-05-19 | Zalevsky Jonathan | Officer, Chief R&D Officer | Open Market Sale | -10,712 | 0.67 | -7,177.04 | -15,2% |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Bronte Capital Management Pty Ltd. | 400,756 | 28,834,394 | 35.33 |
| UBS Group AG | 320,172 | 23,036,375 | 28.23 |
| Russell Investments Group, Ltd. | 106,248 | 7,644,546 | 9.37 |
| MOODY ALDRICH PARTNERS LLC | 89,527 | 6,441,468 | 7.89 |
| ACT CAPITAL MANAGEMENT, LLC | 70,900 | 5,101,255 | 6.25 |
| Swiss National Bank | 47,900 | 3,446,405 | 4.22 |
| Y-Intercept (Hong Kong) Ltd | 26,545 | 1,909,913 | 2.34 |
| Legal & General Group Plc | 16,658 | 1,198,543 | 1.47 |
| Steward Partners Investment Advisory, LLC | 15,526 | 1,117,095 | 1.37 |
| State of New Jersey Common Pension Fund D | 8,288 | 596,322 | 0.73 |
| CenterBook Partners LP | 7,407 | 532,934 | 0.65 |
| KLP KAPITALFORVALTNING AS | 5,200 | 374,140 | 0.46 |
| China Universal Asset Management Co., Ltd. | 4,000 | 287,800 | 0.35 |
| Pictet Asset Management Holding SA | 3,718 | 267,510 | 0.33 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | 3,098 | 222,902 | 0.27 |
| LVW Advisors, LLC | 3,022 | 217,433 | 0.27 |
| Bayforest Capital Ltd | 2,538 | 182,609 | 0.22 |
| Leonteq Securities AG | 2,000 | 143,900 | 0.18 |
| MONTAG A & ASSOCIATES INC | 250 | 17,988 | 0.02 |
| Activest Wealth Management | 200 | 14,390 | 0.02 |